报价延迟最少15分钟:2025/08/26 09:07 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.05/0.12
|
|
企业价值
531.49M
|
| 资产负债 |
|
每股账面净值
2.97
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
200.45M
|
|
每股收益
1.38
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/26 09:07 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. ItsFSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States. |
